Journal of Clinical Densitometry
Volume 11, Issue 3 , Pages 351-359 , July 2008

Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate

  • Thomas J. Beck

      Affiliations

    • Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationAddress correspondence to: Thomas J Beck, ScD, The Johns Hopkins Outpatient Center, 601 North Caroline Street, Suite 4260, Baltimore, MD 21287-0849, USA.
    • ,
  • E. Michael Lewiecki

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA
    • ,
  • Dieter Felsenberg

      Affiliations

    • Muscle and Bone Research Centre, Freie and Humboldt University Berlin, Berlin, Germany
    • ,
  • Yu Liu

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Beiying Ding

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Cesar Libanati

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA

Received 28 December 2007 ,Revised 27 March 2008 ,Accepted 2 April 2008.

References 

  1. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006;119(4A):25S–31S
  2. Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep. 2007;5(1):38–43
  3. Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med. 1995;98(2A):24S–28S
  4. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004;19(2):330–337
  5. Beck T. Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int. 2003;14(Suppl):581–588
  6. Beck TJ, Looker AC, Ruff CB, et al. Structural trends in the aging of femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey duel energy X-ray absorptiometry data. J Bone Miner Res. 2000;15(12):2297–2304
  7. Rivadeneira F, Zillikens MC, De Laet CEDH, et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. J Bone Miner Res. 2007;22(11):1781–1790
  8. Greenspan SL, Beck TJ, Resnick NM, et al. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res. 2005;20(9):1525–1532
  9. Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int. 2006;17(4):575–586
  10. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005;36(6):948–958
  11. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145(3):527–538
  12. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96(7):3540–3545
  13. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2):435–448
  14. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–176
  15. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597–3602
  16. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22(12):1832–1841
  17. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831
  18. Martin RB, Burr DB. Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry. J Biomech. 1984;17(3):195–201
  19. Beck TJ, Looker AC, Ruff CB, et al. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res. 2000;15(12):2297–2304
  20. Khoo BC, Beck TJ, Qiao QH, et al. In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials. Bone. 2005;37(1):112–121
  21. Armitage P, Colton T. Encyclopedia of Biostatistics. 2nd ed.. Chichester, UK: John Wiley and Sons, Ltd; 2005;
  22. Melton LJ, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporosis Int. 1999;9(1):29–37
  23. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18(11):1947–1954
  24. Mackey DC, Lui L-Y, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007;298(20):2381–2388
  25. Kostenuik PJ, Warmington K, Grisanti M, et al. RANKL inhibition with AMG 162, a fully human MAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res. 2005;20(Suppl1):S259
  26. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85
  27. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004;20(8):1291–1300
  28. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. J Clin Invest. 1991;88:2095–2105
  29. Young W. Elastic stability formulas for stress and strain. Roark's formulas for stress and strain. 6th ed.. New York: McGraw-Hill; 1989;688
  30. Mayhew PM, Thomas CD, Clement JG, et al. Relation between age, femoral neck cortical stability, and hip fracture risk. [see comment] Lancet. 2005;366(9480):129–135
  31. Bell KL, Loveridge N, Power J, et al. Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis. J Bone Miner Res. 1999;14(1):111–119
  32. Hillier T, Beck T, Oreskovic T, et al. Predicting long term hip fracture risk with bone mineral density and hip structure in post-menopausal women: the Study of Osteoporotic Fractures (SOF). J Bone Miner Res. 2003;18(Suppl2):S21
  33. Beck TJ, Oreskovic TL, Stone KL, et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res. 2001;16(6):1108–1119
  34. Beck TJ. Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep. 2007;5(2):49–55
  35. Hangartner TN. Thresholding technique for accurate analysis of density and geometry in QCT, pQCT and microCT images. J Musculoskelet Neuronal Interact. 2007;7(1):9–16
  36. Beck T, Brown J, Gustafsson S, et al. In vivo comparison of CT and DXA methods of proximal femur cross-sectional geometry measuement using HSA. J Bone Miner Res. 2007;22(Suppl 1):418–419

PII: S1094-6950(08)00038-3

doi: 10.1016/j.jocd.2008.04.001

Journal of Clinical Densitometry
Volume 11, Issue 3 , Pages 351-359 , July 2008

Article Tools

* Image Usage & Resolution